此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Association of Psychological Distress With Clinical Outcomes in Patients With Digestive System Cancers

2026年11月6日 更新者:Hongyan Li, MD、Xuanwu Hospital, Beijing

Association of Psychological Distress With Clinical Outcomes in Patients With Digestive System Cancers: A Prospective Cohort Study

This prospective observational cohort study aims to investigate the association between psychological distress and clinical outcomes in patients with digestive system cancers, including pancreatic, gastric, and colorectal cancers.

Approximately 100 adult patients who are scheduled to receive first-line systemic anticancer therapy will be enrolled at Xuanwu Hospital, Capital Medical University. Psychological distress will be assessed using the Distress Thermometer (DT), Hospital Anxiety and Depression Scale (HADS), and 12-item General Health Questionnaire (GHQ-12).

Participants will undergo baseline assessments and follow-up evaluations every three months for up to three years. Clinical information, psychological distress scores, laboratory findings, imaging results, and quality-of-life data will be collected.

The primary outcome is progression-free survival (PFS). Secondary outcomes include overall survival (OS), objective response rate (ORR), and quality of life. The study will evaluate whether psychological distress is associated with cancer prognosis after adjusting for potential confounding factors, including cancer stage, treatment regimen, and nutritional status.

As an observational study, no experimental treatment will be assigned, and all participants will receive standard anticancer treatment according to routine clinical practice.

研究概览

地位

主动,不招人

研究类型

观察性的

注册 (估计的)

100

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、24266
        • Xuanwu Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

The study population will consist of approximately 100 adult patients with pathologically confirmed pancreatic, gastric, or colorectal cancer who are scheduled to receive first-line systemic anticancer therapy at the Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China. Eligible patients will be consecutively enrolled according to the predefined inclusion and exclusion criteria. Psychological distress will be assessed at baseline and during follow-up to investigate its association with clinical outcomes, including progression-free survival and overall survival.

描述

Inclusion Criteria:

  • Patients with pathologically confirmed digestive system cancers, including pancreatic cancer, gastric cancer, or colorectal cancer.
  • Male or female patients aged 18 years or older.
  • Patients scheduled to receive first-line systemic anticancer therapy, including chemotherapy, targeted therapy, immunotherapy, or combination therapy, with no systemic treatment for the current cancer lesions within 3 months prior to enrollment.
  • At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
  • Life expectancy of at least 12 weeks, as assessed by the investigator.
  • Willing and able to provide written informed consent to participate in the study.

Exclusion Criteria:

  • History of another malignancy within the past 3 years or concurrent malignancy.
  • Presence of acute or chronic psychiatric disorders, or current treatment with antidepressant or anxiolytic medications.
  • Previous treatment in another investigational drug trial.
  • Inability to complete psychological assessment questionnaires due to cognitive impairment, language barriers, or other conditions that interfere with questionnaire completion.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Progression-Free Survival (PFS)
大体时间:From enrollment to the first documented disease progression or death from any cause, whichever occurs first, assessed up to 3 years.

Progression-free survival (PFS) is defined as the time from study enrollment to the first radiologically confirmed disease progression, as assessed by the investigator according to RECIST version 1.1, or death from any cause, whichever occurs first. PFS will be compared between patients with high and low levels of psychological distress.

From enrollment to the first documented disease progression or death from any cause, whichever occurs first, assessed up to 3 years.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年5月1日

初级完成 (估计的)

2026年12月1日

研究完成 (估计的)

2027年8月1日

研究注册日期

首次提交

2026年10月29日

首先提交符合 QC 标准的

2026年11月6日

首次发布 (实际的)

2026年11月9日

研究记录更新

最后更新发布 (实际的)

2026年11月9日

上次提交的符合 QC 标准的更新

2026年11月6日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅